Targeting EGFR T790M in Advanced Adenocarcinoma of the Lung

Maher Salamoon

Department of Medical Oncology and Hematology, Al Bairouni University Cancer Center, Syria

^*Correspondance to: Maher Salamoon 

 PDF  Full Text Review Article | Open Access

Abstract:

The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs including Gefitinib and erlotinib. Thirdgeneration EGFR TKIs against the T790M mutation have been developed and they are in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816 and PF-06747775. Osimertinib and rociletinib have shown clinical efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs. Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-positive NSCLC. HM61713, ASP8237, EGF816, and PF-06747775 are still in early clinical development. We are discussing the emerging role of 3rd generation anti-EGFR in the treatment of locally advanced and metastatic adenocarcinoma of the lung.

Keywords:

Adenocarcinoma, lung, EGFR, T790M

Cite the Article:

Salamoon M. Targeting EGFR T790M in Advanced Adenocarcinoma of the Lung. Clin Oncol. 2018; 3: 1427.